ArticleBMC health services research2025
Cost-Effectiveness analysis of the 21-Gene platform for guiding treatment decisions for early Hormone-Positive breast cancer: the perspective of the Brazilian public health system.
Article in BMC health services research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe 21-gene platform Oncotype DX helps clinicians identify women with early- stage estrogen receptor (ER)-positive breast cancer who will not benefit from adjuvant chemotherapy. However, it is too expensive to be implemented by the Brazilian public health system (SUS). Therefore, the aim of this study was to assess the cost-effectiveness of a new 21- gene platform for guiding treatment decisions in these patients.
methodsCost-effectiveness analysis, conducted over a 6-month period, based on standard values payable by the SUS for adjuvant hormone therapy and chemotherapy. Effectiveness was measured in quality-adjusted life years, and sensitivity analyses for different hypothetical costs of the 21-gene platform were performed.
resultsWhen all patients were considered, decision tree analysis revealed a benefit of standard clinical risk factor-based approach alone over the use of the 21-gene platform for making treatment decisions. However, for patients classified as high risk according to clinical factors, the 21-gene platform was less expensive than the standard clinical risk factor-based approach, with a platform cost of up to USD 294.75. The incremental cost-effectiveness ratio (ICER) for the platform was lower than that of the 2022 Brazilian gross domestic product per capita (used as the willingness to pay) up to a 21-gene platform cost of USD 1,505.46.
conclusionThe use of the 21-gene platform can be cost effective for guiding treatment decisions in early ER- positive breast cancer treated by the SUS for patients classified at high risk on the basis of clinical factors if a cost limit of US$ 1,505.46 per test is considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.